UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses from the BE HEARD I and BE HEARD II Phase 3 studies of BIMZELX in adults with moderate-to-severe hidradenitis suppurativa (HS). These studies highlight clinically meaningful improvements in skin pain […]